-
Six patients were given a virus that infects the body with the blueprints needed to produce blood-clotting proteins. Four of them could then stop taking their drugs. Just one injection appears to be enough to mean people with haemophilia B no longer need medication, according to an early study in the UK and the US.
BBC News (Hematology) - Tue, 13 December 2011
http://news.bbc.co.uk
-
Young infants and toddlers with sickle cell anemia who received the drug hydroxyurea were no more likely to have cellular genetic damage than those who received a placebo or inactive medicine. Hydroxyurea was approved by the U.S. Food and Drug Administration as a treatment for adults with sickle cell disease in 1998, but it has not yet been approved for use in children. Hydroxyurea reduces the amount of sickle hemoglobin by stimulating the production of fetal hemoglobin, which results in healthier red blood cells and a reduction in the frequency and severity of the complications associated with the disorder.
Baylor College of Medicine (Hematology) - Tue, 13 December 2011
http://www.bcm.edu
-
The U.S. Food and Drug Administration today approved deferiprone to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.
Food and Drug Administration (Hematology) - Wed, 19 October 2011
http://www.fda.gov
-
The use of tranexamic acid during surgeries is associated with less blood losses and less needs of transfusions. According to this statement, with a randomized trial, partly sponsored by pharmaceutical industry (CRASH-2: Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2) the efficacy of this antifibrinolytic has been assessed in 20,211 patients experimenting injuries and bleeding risk. The drug (or placebo) has been given within the first 8 hours after injury; the dose of tranexamic acid has been 1 g within the first 10 minutes, followed by a slow infusion of 1 g during the following 8 hours.
MedNews (Hematology) - Mon, 25 July 2011
http://mn.medsurfnews.com/
-
New research from Karolinska Institutet shows that hydroxyurea, one type of cytotoxic treatment for chronic myeloproliferative blood disorders, does not increase the risk of developing acute leukaemia, as had previously been suspected. Rather, it is the disease itself that mainly increases this risk. Another new study by the same group of researchers shows that mortality from chronic myeloid leukaemia has decreased sharply since the approval of the drug Imatinib as a standard treatment in 2001.
Karolinska Institutet (Hematology) - Tue, 17 May 2011
http://ki.se/ki/jsp/polopoly.jsp?d=130&l=en
-
But one of 10 boys developed leukemia, possibly from treatment, researchers say.
Medscape (Hematology) - Mon, 6 December 2010
http://www.medscape.com
-
After a myocardial infarction, the use of aspirin and clopidogrel is recommended, but many patients in this conditions also need a vitamin-K antagonist. But these drugs together cause an increase in hemorrhagic risk, even severe, and they consequently increase overall morbidity and mortality. In order to verify the safety of a contemporary use of anticoagulation and antiplatelet drugs, then, some researchers in Denmark have identified 40,000 adults in the national registry, with the prescription of one or more of the following drugs: aspirin, clopidogrel, warfarin in the 90 days following myocardial infarction.
MedNews (Hematology) - Wed, 27 October 2010
http://mn.medsurfnews.com/
-
An advance that tracks a patient's hemoglobin levels without drawing blood could drastically cut down the need for extra blood in the operating room.
Scientific American (Hematology) - Mon, 25 October 2010
http://www.sciam.com/
-
Early transfusion of FFP is associated with an increased risk of postinjury MOF, even after adjusting for age, ISS, and PRBC transfusion. Caution is warranted in developing protocols for empirical FFP transfusion. Specifically, transfusion triggers for FFP should be reexamined, as well as the practice of delivering FFP in fixed ratios to the units of PRBCs transfused.
Archives of Surgery (Hematology) - Mon, 25 October 2010
http://archsurg.ama-assn.org/
-
Immunophenotyping by flow cytometry or immunohistochemistry is a clinical standard procedure for diagnosis, classification, and monitoring of hematologic malignancies.
Blood (Hematology) - Tue, 5 October 2010
http://www.bloodjournal.org/